Study Companion: Answers to Clinicians’ Questions About Biosimilar Use in Inflammatory Conditions

To participate in this activity, please:

We have the answers, do you know the questions? If so, you’ll enjoy this Jeopardy style game focused on biosimilars. Biosimilar anti-rheumatologic disease modifying therapies have been approved by the FDA and are becoming increasingly available in the US. Yet, concerns among some clinicians and patients remain. In this activity, Jonathan Kay, MD, discusses the approval process and other issues related to biosimilar development and use so that you can be confident when discussing them with and prescribing them for your patients.

Editor’s Note: The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved applications.

Course Credit:

1 ACPE Contact Hour
1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour


Opens: 2022-04-30
Closes: 2023-04-30

Target Audience:

This activity was developed for rheumatologists, gastroenterologists, dermatologists, primary care physicians, along with nurse practitioners, physician assistants and pharmacists who manage patients who are candidates for a biosimilar therapy.

This activity is supported by an educational grant from Pfizer Inc.

    Presenting Faculty

  • Jonathan Kay, MD

    Timothy S. and Elaine L. Peterson Chair in Rheumatology
    Professor of Medicine and Population and Quantitative Health Sciences
    UMass Chan Medical School and UMass Memorial Medical Center
    Worchester, Massachusetts